Why We Age — The Biology of Aging

Aging is so universal, so relentless, and so familiar that we rarely stop to ask whether it's actually necessary. Every multicellular organism we've studied ages — muscle weakens, DNA accumulates damage, cells lose their ability to divide, systems fail. Death follows. This seems inevitable in the way that gravity seems inevitable — a fact of existence rather than a biological mechanism with identifiable causes.

But it isn't inevitable, or at least it isn't simple. Aging is not programmed obsolescence written into DNA. It's not a countdown timer set at birth. It's the accumulated biological cost of living — the compounding toll of molecular damage that repair systems manage but never fully eliminate. And crucially: those repair systems are not fixed. They vary between species. They can be modulated by genes, diet, and drugs. In certain laboratory organisms, their failure can be delayed dramatically. In some species — the naked mole rat, the Greenland shark, certain trees — aging appears to slow to near-imperceptibility.

This is what makes aging biology one of the most electrifying areas of current research. Not because immortality is on the horizon — it isn't — but because the mechanisms of aging are becoming understood in sufficient detail that the question "can we slow it?" has moved from speculation to experiment. Several of those experiments are succeeding, at least in mice. Whether they'll succeed in humans, and what that would even mean for medicine and society, are questions biology is only beginning to grapple with.

Part I — Why does aging happen at all?

The evolutionary question comes first: if natural selection is so powerful, why hasn't it produced organisms that simply don't age? The answer involves a concept called the disposable soma theory, proposed by evolutionary biologist Thomas Kirkwood in 1977. The key insight: from an evolutionary standpoint, the body is a vehicle for passing genes to the next generation. Investing resources in maintaining the body beyond reproductive age has diminishing evolutionary returns — descendants already exist, and resources spent on the parent's repair could instead go toward producing more offspring.

So natural selection optimizes for reproductive success, not longevity. Repair mechanisms are good enough to keep the body functional through the reproductive period, but not good enough to prevent the eventual accumulation of damage. The soma (body) is "disposable" in the sense that evolution doesn't prioritize its indefinite maintenance. This explains why there's a rough inverse relationship across species between reproductive rate and longevity: mice reproduce fast and die young; whales and elephants reproduce slowly and live long. Each has invested in maintenance proportional to its evolutionary needs.

A related concept is antagonistic pleiotropy — some genes that are beneficial early in life may be harmful later, and selection won't eliminate them because the early benefit outweighs the later cost. The gene encoding p53 is a classic example: high p53 activity suppresses cancer (beneficial in youth) but also drives cellular senescence, which accumulates with age and drives inflammation (harmful later). Evolution can't easily fix this tradeoff without sacrificing cancer suppression.

Part II — The hallmarks of aging

In 2013, a landmark paper by Carlos López-Otín and colleagues identified nine molecular and cellular hallmarks of aging — the biological processes that accumulate with age and collectively drive the decline we recognize as getting old. A 2023 update expanded this to twelve. These hallmarks are not independent — they interact with and amplify each other, creating a cascade of deterioration that accelerates over time.

Genomic instability — the accumulating typos

Every cell division introduces a small number of DNA replication errors. Environmental damage — UV radiation, reactive oxygen species, carcinogens — adds more. DNA repair systems fix the vast majority, but not all. Over decades, the accumulated errors create a genome that diverges increasingly from the original. In most tissues, this has limited consequences — damaged cells are cleared by apoptosis or immune surveillance. But in stem cells — the source of cellular renewal in each tissue — accumulated mutations can drive the loss of stem cell function and, occasionally, cancer.

Beyond sequence mutations, chromosomes accumulate structural damage: breaks, translocations, and the reactivation of transposable elements — ancient mobile DNA sequences (about 45% of the human genome) that are normally silenced by epigenetic mechanisms. As epigenetic silencing weakens with age, transposable elements reactivate and jump around the genome, creating more damage and triggering inflammatory responses. Reactivated transposons are increasingly recognized as drivers of neurodegeneration, immune dysfunction, and cancer in aged tissues.

Telomere attrition — the countdown

We covered telomeres briefly in the modules — the protective caps on chromosome ends that shorten with each cell division because DNA polymerase can't fully replicate the end of a linear chromosome. When telomeres reach a critical length, cells enter a permanent non-dividing state called senescence, or they die. This is not simply a passive countdown: short telomeres activate DNA damage response pathways, trigger the p53 tumor suppressor, and contribute to the senescent secretory phenotype (more on this below).

In most body cells, telomerase — the enzyme that extends telomeres — is silenced after early development. It remains active in stem cells and germ cells, which is why they can sustain long-term division. The deliberate silencing of telomerase in somatic cells is thought to be an anti-cancer mechanism: limiting replicative capacity prevents runaway cell division. The tradeoff is aging. This is another example of antagonistic pleiotropy — the same mechanism that suppresses cancer in youth contributes to tissue decline later in life.

Epigenetic alteration — the program drifting

The epigenome — the pattern of DNA methylation and histone modifications controlling gene expression — changes substantially with age. Some changes are programmatic: the epigenetic clock, identified by Steve Horvath in 2013, tracks hundreds of DNA methylation sites that change with age in a highly predictable pattern. From a blood sample, you can estimate a person's biological age with remarkable accuracy. The clock predicts mortality better than chronological age — people whose biological age exceeds their chronological age die earlier on average.

What's causing the drift? Partly the accumulating genomic damage described above — damage signals alter epigenetic patterns. Partly the dilution of epigenetic information during cell division — the machinery that copies methylation marks during replication is imperfect. Whatever the cause, aged cells show aberrant gene expression: genes that should be active are silenced, genes that should be silenced are active. This dysregulation contributes to every aspect of cellular aging.

Cellular senescence — the zombie cells

Senescent cells are cells that have permanently stopped dividing — triggered by telomere exhaustion, DNA damage, oncogene activation, or other stresses — but haven't died. They linger in tissues, metabolically active, and secrete a complex cocktail of inflammatory cytokines, proteases, and growth factors called the senescence-associated secretory phenotype (SASP). The SASP recruits immune cells, promotes inflammation, degrades the extracellular matrix, and — most troublingly — can induce senescence in neighboring cells, spreading dysfunction through a tissue like a slow infection.

Senescence is not purely harmful. In young organisms, senescent cells play important roles: they arrest the division of cells with damaged DNA (preventing cancer), promote wound healing, and contribute to embryonic development. The problem is accumulation. Young immune systems efficiently clear senescent cells; aging immune systems lose this capacity. Senescent cells accumulate progressively, and their SASP drives a low-grade chronic inflammation — sometimes called inflammaging — that underlies cardiovascular disease, neurodegeneration, metabolic disease, and many cancers.

Mitochondrial dysfunction and proteostasis loss

Mitochondria deteriorate with age through multiple mechanisms: their own circular DNA accumulates mutations (mitochondrial DNA has no histone protection and limited repair); the mitochondrial membrane potential declines; the fission/fusion dynamics that maintain mitochondrial quality control slow down. Aged mitochondria produce less ATP and more reactive oxygen species — damaged electrons that leak from the electron transport chain and damage lipids, proteins, and DNA. This creates a vicious cycle: mitochondrial damage increases ROS production, which causes more mitochondrial damage.

Loss of proteostasis is the parallel failure of protein quality control. Cells maintain proteostasis through the proteasome (which degrades damaged proteins) and autophagy (which engulfs and recycles entire organelles and protein aggregates). Both decline with age. The result: misfolded and damaged proteins accumulate. This is directly relevant to neurodegeneration — Alzheimer's is characterized by amyloid-beta plaques and tau tangles; Parkinson's by alpha-synuclein aggregates; Huntington's by mutant huntingtin aggregates. These are all failures of proteostasis, accumulating over decades before symptoms appear.

Part III — Can aging be slowed?

The honest answer, in 2024, is: yes, in laboratory organisms, substantially. In humans, probably modestly through lifestyle, and perhaps more substantially through interventions that are still being tested. The gap between mouse results and human translation is real and important — many interventions that extend mouse lifespan have failed or shown modest effects in human trials. But the mechanistic understanding is advancing fast enough that most researchers in the field believe meaningful human lifespan extension is achievable within decades, not centuries.

Caloric restriction and rapamycin

Caloric restriction — eating 20–40% fewer calories than ad libitum — extends lifespan in every organism tested, from yeast to mice to some primates. The mechanism involves nutrient-sensing pathways: low nutrient availability activates AMPK and inhibits mTOR (mechanistic target of rapamycin) and IGF-1 signaling, shifting cellular metabolism toward maintenance and repair rather than growth. This makes evolutionary sense — in times of food scarcity, investment in somatic maintenance increases survival odds until food returns.

Rapamycin, an inhibitor of mTOR, mimics aspects of caloric restriction pharmacologically. When given to mice starting at 20 months of age (equivalent to roughly 60 human years), it extended median lifespan by 14% in males and 38% in females — remarkable for an intervention started so late. It's one of the most reproducible longevity interventions in mouse biology. Human rapamycin trials are ongoing; at low doses used periodically, it appears safe. At the immunosuppressive doses used in transplant medicine, it causes significant side effects. The sweet spot for longevity benefits without toxicity in humans is under active investigation.

NAD+ precursors

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for energy metabolism and a substrate for sirtuins — enzymes that regulate epigenetics, DNA repair, and stress responses. NAD+ levels decline approximately 50% between youth and middle age in most tissues. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors that raise NAD+ levels. In mice, NAD+ precursors have improved muscle function, cognitive performance, DNA repair, and metabolic health in aged animals. Human trials show NAD+ levels do rise with supplementation, but whether the functional benefits seen in mice translate is not yet established. Both are widely used as supplements; the evidence for human benefit remains promising but preliminary.